Building on the success of the PD-1 inhibitor Opdivo (Bristol-Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, Keytruda (Merck & Co.) plus Inlyta (Pfizer), Bavencio (Merck KGaA / Pfizer) plus Inlyta, are revolutionizing the treatment of advanced disease. Angiogenesis inhibitors such as Sutent (Pfizer), Votrient (Novartis), and Cabometyx (Exelixis / Ipsen) remain a key feature of first-line treatment. The entry and increased uptake of Cabometyx and Opdivo in this setting is beginning to shift Inlyta and Lenvima / Kisplyx (Eisai) plus Afinitor (Novartis) to later lines. Furthermore, following Sutent’s approval for high-risk early-stage (stage I-III) patients, multiple immune checkpoint inhibitors are also anticipated to transition to the early-stage setting. The renal cell carcinoma market remains highly competitive and dynamic, but the developer of an efficacious therapy can expect to reap high commercial rewards.

Questions Answered:

  • How are the early-stage and advanced or metastatic drug-treatable renal cell carcinoma populations defined, and how will drug-treatment rates evolve over the forecast period?
  • What is the current treatment landscape for renal cell carcinoma, and what are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What is the future outlook for key combination regimens in renal cell carcinoma? How will these combination regimens be differentiated, and which look the most promising?
  • Which emerging therapies do we forecast to enter the renal cell carcinoma market? What uptake and sales are these therapies anticipated to secure ?

Contents Highlights

Geographies: United States, EU5, Japan

Primary Research: 19 country-specific interviews with thought-leading medical oncologists and urologists. Supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed and recurrent incidence of renal cell carcinoma by country, segmented by drug-treatable and -treated early stage and locally advanced or metastatic disease, and line of therapy.

Forecast: 10-year, annualized, drug-level sales and patient share of key renal cell carcinoma therapies through 2029, segmented by brands/generics and epidemiological sub-populations.

Emerging Therapies: Phase III/PR: 7 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
    • Key Updates
      • May 2020
      • March 2020
      • December 2019
      • July 2019
      • May 2019
      • March 2019
      • December 2018
      • October 2018
    • Market Outlook
      • Key Findings
      • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Renal Cell Carcinoma?
        • What Factors Are Constraining the Market for Renal Cell Carcinoma?
      • Segment-Specific Trends
        • Early-Stage (Stage I-III) Renal Cell Carcinoma
        • First-Line Advanced or Metastatic Renal Cell Carcinoma
        • Second- and Later-Line Advanced or Metastatic Renal Cell Carcinoma
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Pathophysiology
        • Staging and Classification
        • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Renal Cell Carcinoma
        • Recurrent Incident Cases of Renal Cell Carcinoma
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immune Checkpoint Inhibitors
        • Angiogenesis Inhibitors
        • mTOR Inhibitors
      • Medical Practice
        • Early-Stage Renal Cell Carcinoma: Stages I-III
        • First-Line Advanced or Metastatic Renal Cell Carcinoma: Stage IV
        • Second-Line Advanced or Metastatic Renal Cell Carcinoma
        • Third- and Fourth-Line Advanced or Metastatic Renal Cell Carcinoma
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Renal Cell Carcinoma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Immune Checkpoint Inhibitors
        • Angiogenesis Inhibitors
        • Cytokines
        • Histone Deacetylase Inhibitors
        • Hypoxia-Inducible Factor (HIF)-2-Alpha Inhibitors
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Renal Cell Carcinoma Bibliography

Author(s): Priyanka Mehra, B.Tech; Sorcha Cassidy M.Res., Ph.D

Priyanka Mehra is a Business Insights Analyst in the oncology team at Decision Resources Group. She has 5+ years of work experience in pharmaceutical research and analytics, involving management and execution of various strategic analysis projects across multiple oncology indications, secondary and primary research and competitive intelligence. Previously, she worked as an Associate Consultant with Prescient Healthcare Group where she handled Biosimilars projects for global pharmaceutical clients and designed brand and commercial strategy solutions on a variety of therapy areas, including oncology, immunology and inflammatory diseases. Prior to Prescient, she worked as a Senior Analyst with Smart Analyst where she worked on indication prioritization and clinical landscapes for major oncology indications such as NHL, NSCLC and CRC. She has also worked as a Senior Analyst with BioXcel Corporation where she was involved with projects on clinical trials and pipeline analysis, performance benchmarking, scouting and product profiling.

Sorcha Cassidy , is an Associate Director in the Oncology team at Decision Resources ; Dr. Cassidy manages a team of analysts who conduct extensive primary and secondary market research on several Oncology indications across the major pharmaceutical markets. She also provides sales and client support across all oncology products. She has in-depth expertise in competitive intelligence, secondary and primary market research, and delivering strategic insights that address key client business questions. Dr. Cassidy holds an and in Immunology from Imperial College London where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIR) on natural killer (NK) cells in various diseases and published several peer-reviewed papers. Prior to joining the company, Dr. Cassidy previously worked as a Market Research Manager in Janssen UK and has extensive experience working across multiple Oncology indications at GlobalData and FirstWord Pharma.

Related Reports

Renal Cell Carcinoma | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma ...

View Details

Renal Cell Carcinoma | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalenc...

View Details

Renal Cell Carcinoma | Current Treatment | Detailed, Expanded Analysis (US)

Market O

View Details